#AAN2018 – Early Data Supports Clinical Trial Now Testing IONIS-MAPTRx in Alzheimer’s Patients

#AAN2018 – Early Data Supports Clinical Trial Now Testing IONIS-MAPTRx in Alzheimer’s Patients
An injection of IONIS-MAPTRx resulted in a 70 percent decrease in tau protein produced in the brains of non-human primates, researchers at  Ionis Pharmaceuticals, the potential treatment's maker, are reporting. These positive pre-clinical findings helped in the design of a first clinical study, now underway and enrolling, that will assess IONIS-MAPTRx in people with mild Alzheimer’s disease. The results are in the oral presentation “Design of the First-in-Human Study of IONIS-MAPTRx, a Tau-lowering Antisense Oligonucleotide, in Patients With Alzheimer Disease” set to be given April 22 at the 
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *